Nothing Special   »   [go: up one dir, main page]

PL3177608T3 - Inhibitory kinazy białkowej C i sposoby ich zastosowania - Google Patents

Inhibitory kinazy białkowej C i sposoby ich zastosowania

Info

Publication number
PL3177608T3
PL3177608T3 PL15750138T PL15750138T PL3177608T3 PL 3177608 T3 PL3177608 T3 PL 3177608T3 PL 15750138 T PL15750138 T PL 15750138T PL 15750138 T PL15750138 T PL 15750138T PL 3177608 T3 PL3177608 T3 PL 3177608T3
Authority
PL
Poland
Prior art keywords
inhibitors
methods
protein kinase
kinase
protein
Prior art date
Application number
PL15750138T
Other languages
English (en)
Inventor
Michael Joseph Luzzio
Julien Papillon
Michael Scott Visser
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=53836145&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL3177608(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of PL3177608T3 publication Critical patent/PL3177608T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Transplantation (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
PL15750138T 2014-08-06 2015-08-05 Inhibitory kinazy białkowej C i sposoby ich zastosowania PL3177608T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462033679P 2014-08-06 2014-08-06
EP15750138.8A EP3177608B1 (en) 2014-08-06 2015-08-05 Protein kinase c inhibitors and methods of their use
PCT/IB2015/055951 WO2016020864A1 (en) 2014-08-06 2015-08-05 Protein kinase c inhibitors and methods of their use

Publications (1)

Publication Number Publication Date
PL3177608T3 true PL3177608T3 (pl) 2020-03-31

Family

ID=53836145

Family Applications (1)

Application Number Title Priority Date Filing Date
PL15750138T PL3177608T3 (pl) 2014-08-06 2015-08-05 Inhibitory kinazy białkowej C i sposoby ich zastosowania

Country Status (42)

Country Link
US (7) US9452998B2 (pl)
EP (2) EP3514151A1 (pl)
JP (1) JP6644765B2 (pl)
KR (2) KR102518945B1 (pl)
CN (2) CN113214246A (pl)
AP (1) AP2017009729A0 (pl)
AR (1) AR101456A1 (pl)
AU (1) AU2015298364B2 (pl)
BR (1) BR112017002263B1 (pl)
CA (1) CA2956996C (pl)
CL (1) CL2017000290A1 (pl)
CO (1) CO2017001049A2 (pl)
CR (1) CR20170036A (pl)
CU (1) CU24465B1 (pl)
CY (1) CY1122407T1 (pl)
DK (1) DK3177608T3 (pl)
DO (1) DOP2017000035A (pl)
EA (1) EA033361B1 (pl)
EC (1) ECSP17013903A (pl)
ES (1) ES2754248T3 (pl)
GT (1) GT201700025A (pl)
HR (1) HRP20192224T1 (pl)
HU (1) HUE047862T2 (pl)
IL (1) IL250318B (pl)
JO (1) JO3589B1 (pl)
LT (1) LT3177608T (pl)
MX (1) MX2017001640A (pl)
MY (1) MY195488A (pl)
NI (1) NI201700012A (pl)
PE (1) PE20170241A1 (pl)
PH (1) PH12017500215A1 (pl)
PL (1) PL3177608T3 (pl)
PT (1) PT3177608T (pl)
RS (1) RS59692B1 (pl)
SG (1) SG11201700664UA (pl)
SI (1) SI3177608T1 (pl)
SV (1) SV2017005373A (pl)
TN (1) TN2017000032A1 (pl)
TW (1) TWI680968B (pl)
UY (1) UY36258A (pl)
WO (1) WO2016020864A1 (pl)
ZA (1) ZA201700786B (pl)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3589B1 (ar) 2014-08-06 2020-07-05 Novartis Ag مثبطات كيناز البروتين c وطرق استخداماتها
MX2018001903A (es) * 2015-08-14 2018-06-20 Novartis Ag Inhibidores de mdm2 para el tratamiento de melanoma uveal.
US11154555B2 (en) 2016-07-14 2021-10-26 Mingsight Pharmaceuticals, Inc. Treatment of cancer
WO2019053595A1 (en) * 2017-09-12 2019-03-21 Novartis Ag INHIBITORS OF PROTEIN KINASE C FOR THE TREATMENT OF CHOROIDAL MELLANOMA
IL277071B2 (en) 2018-03-08 2024-07-01 Incyte Corp Aminopyrizine diol compounds as PI3K–y inhibitors
CN110496223B (zh) * 2018-05-17 2021-09-10 复旦大学附属肿瘤医院 一种治疗非霍奇金氏淋巴瘤的药物组合物
US11046658B2 (en) 2018-07-02 2021-06-29 Incyte Corporation Aminopyrazine derivatives as PI3K-γ inhibitors
WO2020092924A1 (en) * 2018-11-02 2020-05-07 Board Of Regents, The University Of Texas System Combination therapy for the treatment of egfr tyrosine kinase inhibitor resistant cancer
US20220305008A1 (en) * 2019-01-07 2022-09-29 Ideaya Biosciences, Inc. Treatment of cancer having gnaq or gna11 genetic mutations with protein kinase c inhibitors
KR102405055B1 (ko) * 2019-01-16 2022-06-07 상하이 잉리 파마슈티컬 컴퍼니 리미티드 모르폴리노퀴나졸린 화합물의 제조방법 및 이의 중간체
WO2020198469A1 (en) * 2019-03-27 2020-10-01 Ideaya Biosciences Inc. Method for treating epidermal growth factor receptor-driven cancers with protein kinase c inhibitors in combination with an egfr-tyrosine kinase inhibitor
AU2020386903A1 (en) * 2019-11-18 2022-06-09 Ideaya Biosciences, Inc. Dosing regimens for a protein kinase C inhibitor
BR112022024071A2 (pt) 2020-05-27 2022-12-20 Axial Therapeutics Inc Compostos moduladores de tlr2, composições farmacêuticas e usos dos mesmos
PL243663B1 (pl) * 2020-06-29 2023-09-25 Univ Medyczny Im Piastow Slaskich We Wroclawiu Zastosowanie wanikozydów
EP4210704A4 (en) * 2020-09-08 2024-08-28 Ideaya Biosciences Inc PHARMACEUTICAL COMBINATION AND ANTITUMOR TREATMENT
WO2024125543A1 (zh) * 2022-12-16 2024-06-20 苏州科睿思制药有限公司 达洛色替的晶型及其制备方法和用途

Family Cites Families (170)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US15677A (en) * 1856-09-02 Improved cutting device for harvesters
US4294926A (en) 1979-06-15 1981-10-13 Merck & Co., Inc. Hypocholesteremic fermentation products and process of preparation
US4231938A (en) 1979-06-15 1980-11-04 Merck & Co., Inc. Hypocholesteremic fermentation products and process of preparation
US4319039A (en) 1979-06-15 1982-03-09 Merck & Co., Inc. Preparation of ammonium salt of hypocholesteremic fermentation product
US4444784A (en) 1980-08-05 1984-04-24 Merck & Co., Inc. Antihypercholesterolemic compounds
MX7065E (es) 1980-06-06 1987-04-10 Sankyo Co Un procedimiento microbiologico para preparar derivados de ml-236b
JPS5889191A (ja) 1981-11-20 1983-05-27 Sankyo Co Ltd ３−ヒドロキシ−ｍｌ−２３６ｂ誘導体の製造法
WO1984002131A1 (en) 1982-11-22 1984-06-07 Sandoz Ag Analogs of mevalolactone and derivatives thereof, processes for their production, pharmaceutical compositions containing them and their use as pharmaceuticals
US5354772A (en) 1982-11-22 1994-10-11 Sandoz Pharm. Corp. Indole analogs of mevalonolactone and derivatives thereof
US4911165A (en) 1983-01-12 1990-03-27 Ethicon, Inc. Pliabilized polypropylene surgical filaments
US4681893A (en) 1986-05-30 1987-07-21 Warner-Lambert Company Trans-6-[2-(3- or 4-carboxamido-substituted pyrrol-1-yl)alkyl]-4-hydroxypyran-2-one inhibitors of cholesterol synthesis
US4885314A (en) 1987-06-29 1989-12-05 Merck & Co., Inc. Novel HMG-CoA reductase inhibitors
US4782084A (en) 1987-06-29 1988-11-01 Merck & Co., Inc. HMG-COA reductase inhibitors
US4820850A (en) 1987-07-10 1989-04-11 Merck & Co., Inc. Process for α-C-alkylation of the 8-acyl group on mevinolin and analogs thereof
US5180589A (en) 1988-03-31 1993-01-19 E. R. Squibb & Sons, Inc. Pravastatin pharmaceuatical compositions having good stability
US5030447A (en) 1988-03-31 1991-07-09 E. R. Squibb & Sons, Inc. Pharmaceutical compositions having good stability
US4916239A (en) 1988-07-19 1990-04-10 Merck & Co., Inc. Process for the lactonization of mevinic acids and analogs thereof
US5290946A (en) 1988-10-13 1994-03-01 Sandoz Ltd. Processes for the synthesis of 3-(substituted indolyl-2-yl)propenaldehydes
US5118853A (en) 1988-10-13 1992-06-02 Sandoz Ltd. Processes for the synthesis of 3-disubstituted aminoacroleins
US4929437A (en) 1989-02-02 1990-05-29 Merck & Co., Inc. Coenzyme Q10 with HMG-CoA reductase inhibitors
US5189164A (en) 1989-05-22 1993-02-23 Sandoz Ltd. Processes for the synthesis of syn-(E)-3,5-dihydroxy-7-substituted hept-6-enoic and heptanoic acids and derivatives and intermediates thereof
FI94339C (fi) 1989-07-21 1995-08-25 Warner Lambert Co Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi
PH27357A (en) 1989-09-22 1993-06-21 Fujisawa Pharmaceutical Co Pyrazole derivatives and pharmaceutical compositions comprising the same
US5420245A (en) 1990-04-18 1995-05-30 Board Of Regents, The University Of Texas Tetrapeptide-based inhibitors of farnesyl transferase
US5475085A (en) 1991-02-07 1995-12-12 Molecumetics, Ltd. Conformationally restricted mimetics of beta turns and beta bulges and peptides containing the same
HU217629B (hu) 1991-12-12 2000-03-28 Novartis Ag. Eljárás fluvasztatint tartalmazó stabilizált gyógyszerkészítmények előállítására
US5604260A (en) 1992-12-11 1997-02-18 Merck Frosst Canada Inc. 5-methanesulfonamido-1-indanones as an inhibitor of cyclooxygenase-2
EP0604181A1 (en) 1992-12-21 1994-06-29 Eli Lilly And Company Antitumor compositions and method of treatment
AU6027694A (en) 1993-01-15 1994-08-15 G.D. Searle & Co. Novel 3,4-diaryl thiophenes and analogs thereof having use as antiinflammatory agents
WO1994019357A1 (en) 1993-02-23 1994-09-01 Merrell Dow Pharmaceuticals Inc. Farnesyl:protein transferase inhibitors as anticancer agents
US5298627A (en) 1993-03-03 1994-03-29 Warner-Lambert Company Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis
US5409944A (en) 1993-03-12 1995-04-25 Merck Frosst Canada, Inc. Alkanesulfonamido-1-indanone derivatives as inhibitors of cyclooxygenase
CA2118985A1 (en) 1993-04-02 1994-10-03 Dinesh V. Patel Heterocyclic inhibitors of farnesyl protein transferase
EP0698015A1 (en) 1993-05-14 1996-02-28 Genentech, Inc. Preparation of n-cyanodithioimino-carbonates and 3-mercapto-5-amino-1h-1,2,4-triazole
US5602098A (en) 1993-05-18 1997-02-11 University Of Pittsburgh Inhibition of farnesyltransferase
US5380738A (en) 1993-05-21 1995-01-10 Monsanto Company 2-substituted oxazoles further substituted by 4-fluorophenyl and 4-methylsulfonylphenyl as antiinflammatory agents
US5474995A (en) 1993-06-24 1995-12-12 Merck Frosst Canada, Inc. Phenyl heterocycles as cox-2 inhibitors
GB9602877D0 (en) 1996-02-13 1996-04-10 Merck Frosst Canada Inc 3,4-Diaryl-2-hydroxy-2,5- dihydrofurans as prodrugs to cox-2 inhibitors
US5436265A (en) 1993-11-12 1995-07-25 Merck Frosst Canada, Inc. 1-aroyl-3-indolyl alkanoic acids and derivatives thereof useful as anti-inflammatory agents
EP0670314A4 (en) 1993-09-22 1996-04-10 Kyowa Hakko Kogyo Kk FARNESYL-TRANSFERASE INHIBITOR.
US5719148A (en) 1993-10-15 1998-02-17 Schering Corporation Tricyclic amide and urea compounds useful for inhibition of g-protein function and for treatment of proliferative diseases
US5721236A (en) 1993-10-15 1998-02-24 Schering Corporation Tricyclic carbamate compounds useful for inhibition of G-protein function and for treatment of proliferative diseases
IL111257A0 (en) 1993-10-15 1994-12-29 Schering Corp Tricyclic sulfonamide compounds useful for inhibition of g-protein function and for treatment of proliferative diseases
JP2875393B2 (ja) 1993-10-15 1999-03-31 シェーリング コーポレイション Ｇ−タンパク質機能の阻害および増殖性疾患の治療に有用な三環式カルバメート化合物
US5661152A (en) 1993-10-15 1997-08-26 Schering Corporation Tricyclic sulfonamide compounds useful for inhibition of G-protein function and for treatment of proliferative diseases
IL111235A (en) 1993-10-15 2001-03-19 Schering Plough Corp Medicinal preparations for inhibiting protein G activity and for the treatment of malignant diseases, containing tricyclic compounds, some such new compounds and a process for the preparation of some of them
NZ275037A (en) 1993-10-25 1998-01-26 Parke Davis & Co Substituted tetra- and pentapeptide inhibitors of protein as farnesyl transferase inhibitors
US5344991A (en) 1993-10-29 1994-09-06 G.D. Searle & Co. 1,2 diarylcyclopentenyl compounds for the treatment of inflammation
US5783593A (en) 1993-11-04 1998-07-21 Abbott Laboratories Inhibitors of squalene synthetase and protein farnesyltransferase
JPH08505646A (ja) 1993-11-04 1996-06-18 アボツト・ラボラトリーズ スクアレンシンテターゼ及びプロテインファルネシルトランスフェラーゼのインヒビターとしてのシクロブタン誘導体
HUT75308A (en) 1993-11-05 1997-05-28 Warner Lambert Co Substituted di- and tripeptide inhibitors of protein:farnesyl transferase
US5466823A (en) 1993-11-30 1995-11-14 G.D. Searle & Co. Substituted pyrazolyl benzenesulfonamides
SG63570A1 (en) 1993-12-07 1999-03-30 Lilly Co Eli Protein kinase c inhibitors
US5484799A (en) 1993-12-09 1996-01-16 Abbott Laboratories Antifungal dorrigocin derivatives
PT817627E (pt) 1993-12-23 2005-07-29 Lilly Co Eli Inibidores da proteina cinase c
US5545636A (en) 1993-12-23 1996-08-13 Eli Lilly And Company Protein kinase C inhibitors
US5393790A (en) 1994-02-10 1995-02-28 G.D. Searle & Co. Substituted spiro compounds for the treatment of inflammation
WO1995024612A1 (de) 1994-03-07 1995-09-14 International Business Machines Corporation Verfahren und vorrichtung zur schnellen interpolation von zwischenwerten aus periodischen phasenverschobenen signalen und zur erkennung von defekten in einem drehkörper
US5840918A (en) 1994-03-15 1998-11-24 Eisai Co., Ltd. Isoprenyl transferase inhibitors
HUT72440A (en) 1994-03-31 1996-04-29 Bristol Myers Squibb Co Imidazole-containing inhibitors of farnesyl protein transferase and pharmaceutical compositions containing them
US5523430A (en) 1994-04-14 1996-06-04 Bristol-Myers Squibb Company Protein farnesyl transferase inhibitors
US5510510A (en) 1994-05-10 1996-04-23 Bristol-Meyers Squibb Company Inhibitors of farnesyl protein transferase
US5563255A (en) 1994-05-31 1996-10-08 Isis Pharmaceuticals, Inc. Antisense oligonucleotide modulation of raf gene expression
CN1150419A (zh) 1994-06-10 1997-05-21 罗纳-布朗克罗莱尔股份有限公司 新的法呢基转移酶抑制剂、其制法及其药物组合物
US5571792A (en) 1994-06-30 1996-11-05 Warner-Lambert Company Histidine and homohistidine derivatives as inhibitors of protein farnesyltransferase
WO1996005529A1 (en) 1994-08-09 1996-02-22 Micron Optics, Inc. Temperature compensated fiber fabry-perot filters
ATE188464T1 (de) 1994-08-11 2000-01-15 Banyu Pharma Co Ltd Substituierte amidderivate
CA2155448A1 (en) 1994-08-11 1996-02-12 Katerina Leftheris Inhibitors of farnesyl protein transferase
WO1996005169A1 (fr) 1994-08-12 1996-02-22 Banyu Pharmaceutical Co., Ltd. Derive d'acide amique n,n-bisubstitue
DE4429506B4 (de) 1994-08-19 2007-09-13 Degussa Gmbh Verfahren zur Extraktion natürlicher Carotinoid-Farbstoffe
DE4429653C2 (de) 1994-08-20 1997-04-03 Anton Dr More Konverter und Verfahren zum Frischen von Metallschmelzen insbesondere von Roheisen zu Stahl
KR100389754B1 (ko) 1994-11-22 2003-10-17 코닌클리즈케 필립스 일렉트로닉스 엔.브이. 반도체장치
AU3971295A (en) 1994-12-09 1996-06-26 Warner-Lambert Company Substituted tetra- and pentapeptide inhibitors of protein:farnesyl transferase
EA000164B1 (ru) 1995-01-09 1998-10-29 Магла Интернэшнл Лтд. Состав для печати изображения на поверхности изделия из каучукового латекса, способ печати изображения и изделия из каучукового латекса
AU4915796A (en) 1995-01-12 1996-07-31 University Of Pittsburgh Inhibitors of prenyl transferases
FR2729390A1 (fr) 1995-01-18 1996-07-19 Rhone Poulenc Rorer Sa Nouveaux inhibiteurs de farnesyl transferase, leur preparation et les compositions pharmaceutiques qui les contiennent
FR2730491B1 (fr) 1995-02-09 1997-03-14 Rhone Poulenc Rorer Sa Nouveaux inhibiteurs de farnesyl transferase, leur preparation et les compositions pharmaceutiques qui les contiennent
FR2730492B1 (fr) 1995-02-09 1997-03-14 Rhone Poulenc Rorer Sa Nouveaux inhibiteurs de farnesyl transferase, leur preparation et les compositions pharmaceutiques qui les contiennent
US5633272A (en) 1995-02-13 1997-05-27 Talley; John J. Substituted isoxazoles for the treatment of inflammation
US5700806A (en) 1995-03-24 1997-12-23 Schering Corporation Tricyclic amide and urea compounds useful for inhibition of G-protein function and for treatment of proliferative diseases
US5684013A (en) 1995-03-24 1997-11-04 Schering Corporation Tricyclic compounds useful for inhibition of g-protein function and for treatment of proliferative diseases
IL117580A0 (en) 1995-03-29 1996-07-23 Merck & Co Inc Inhibitors of farnesyl-protein transferase and pharmaceutical compositions containing them
US5891872A (en) 1995-04-07 1999-04-06 Schering Corporation Tricyclic compounds
ZA962694B (en) 1995-04-07 1996-10-03 Schering Corp Carbonyl piperazinyl and piperidinyl compounds
IL117798A (en) 1995-04-07 2001-11-25 Schering Plough Corp Tricyclic compounds useful for inhibiting the function of protein - G and for the treatment of malignant diseases, and pharmaceutical preparations containing them
US5712280A (en) 1995-04-07 1998-01-27 Schering Corporation Tricyclic compounds useful for inhibition of G-protein function and for treatment of proliferative diseases
US5831115A (en) 1995-04-21 1998-11-03 Abbott Laboratories Inhibitors of squalene synthase and protein farnesyltransferase
IL118101A0 (en) 1995-05-03 1996-09-12 Abbott Lab Inhibitors of farnesyltransferase
US5919780A (en) 1995-06-16 1999-07-06 Warner Lambert Company Tricyclic inhibitors of protein farnesyltransferase
FR2736641B1 (fr) 1995-07-10 1997-08-22 Rhone Poulenc Rorer Sa Nouveaux inhibiteurs de farnesyl transferase, leur preparation et les compositions pharmaceutiques qui les contiennent
AT402617B (de) 1995-07-11 1997-07-25 Datacon Schweitzer & Zeindl Gm Anlage zum automatisierten, hermetischen anlage zum automatisierten, hermetischen verschliessen von gehäusen verschliessen von gehäusen
FR2736638B1 (fr) 1995-07-12 1997-08-22 Rhone Poulenc Rorer Sa Nouveaux inhibiteurs de farnesyl transferase, leur preparation et les compositions pharmaceutiques qui les contiennent
CH690163A5 (fr) 1995-07-28 2000-05-31 Symphar Sa Dérivés gem-diphosphonates substitués utiles en tant qu'agents anti-cancers.
US6020343A (en) 1995-10-13 2000-02-01 Merck Frosst Canada, Inc. (Methylsulfonyl)phenyl-2-(5H)-furanones as COX-2 inhibitors
AU7597596A (en) 1995-11-06 1997-05-29 University Of Pittsburgh Inhibitors of protein isoprenyl transferases
PT1186606E (pt) 1995-11-17 2004-08-31 Biotechnolog Forschung Mbh Gbf Derivados do epotilone sua preparacao e utilizacao
DK0776895T3 (da) 1995-11-20 1999-06-23 Lilly Co Eli Proteinkinase C inhibitor
AU704139B2 (en) 1995-11-22 1999-04-15 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
JP3257559B2 (ja) 1995-12-08 2002-02-18 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ ファルネシルタンパク質トランスフェラーゼ阻害（イミダゾール−５−イル）メチル−２−キノリノン誘導体
TW350844B (en) 1995-12-22 1999-01-21 Schering Corp Tricyclic amides useful to inhibition of G-protein function and for treatment of proliferative diseases
US6008372A (en) 1996-01-16 1999-12-28 Warner-Lambert Company Substituted dinaphthylmethyl and diheteroarylmethylacetyl histidine inhibitors of protein farnesyltransferase
US6673927B2 (en) 1996-02-16 2004-01-06 Societe De Conseils De Recherches Et D'applications Scientifiques, S.A.S. Farnesyl transferase inhibitors
EP0944388A4 (en) 1996-04-03 2001-08-16 Merck & Co Inc INHIBITORS OF FARNESYL PROTEIN TRANSFERASE
ME00768B (me) 1996-04-12 2011-10-10 Searle Llc Derivati supstituisanih benzol sulfonamida kao pro-lekovi cox-2 inhibitora
AU728477B2 (en) 1996-05-22 2001-01-11 Warner-Lambert Company Inhibitors of protein farnesyltransferase
CA2260216A1 (en) 1996-07-15 1998-01-22 Bristol-Myers Squibb Company Thiadioxobenzodiazepine inhibitors of farnesyl protein transferase
US5861419A (en) 1996-07-18 1999-01-19 Merck Frosst Canad, Inc. Substituted pyridines as selective cyclooxygenase-2 inhibitors
CA2273083C (en) 1996-12-03 2012-09-18 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto, analogues and uses thereof
CA2276150A1 (en) 1996-12-30 1998-07-09 Steven D. Young Inhibitors of farnesyl-protein transferase
EP1003374A1 (en) 1996-12-30 2000-05-31 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
IL144578A0 (en) 1999-01-29 2002-05-23 Imclone Systems Inc Antibodies specific to kdr and uses thereof
GB9904387D0 (en) 1999-02-25 1999-04-21 Pharmacia & Upjohn Spa Antitumour synergistic composition
WO2000061186A1 (en) 1999-04-08 2000-10-19 Arch Development Corporation Use of anti-vegf antibody to enhance radiation in cancer therapy
AU774748B2 (en) 1999-10-27 2004-07-08 Cytokinetics, Inc. Methods and compositions utilizing quinazolinones
US6545004B1 (en) 1999-10-27 2003-04-08 Cytokinetics, Inc. Methods and compositions utilizing quinazolinones
JP2003520854A (ja) 2000-01-27 2003-07-08 サイトビア インコーポレイテッド カスパーゼのアクチベーターおよびアポトーシスのインデューサーとしての置換ニコチンアミドおよび類似物およびそれらの使用
US6737957B1 (en) * 2000-02-16 2004-05-18 Verance Corporation Remote control signaling using audio watermarks
US6645970B2 (en) 2000-11-07 2003-11-11 Novartis Ag Indolylmaleimide derivatives
SG159378A1 (en) 2000-11-07 2010-03-30 Novartis Ag Indolylmaleimide derivatives as protein kinase c inhibitors
US6958334B2 (en) 2001-04-10 2005-10-25 Merck & Co., Inc. Inhibitors of Akt activity
AU2002307163B2 (en) 2001-04-10 2006-06-29 Merck & Co., Inc. A method of treating cancer
AU2002252614B2 (en) 2001-04-10 2006-09-14 Merck Sharp & Dohme Corp. Inhibitors of Akt activity
WO2002083139A1 (en) 2001-04-10 2002-10-24 Merck & Co., Inc. Inhibitors of akt activity
SE0102439D0 (sv) 2001-07-05 2001-07-05 Astrazeneca Ab New compounds
SE0102438D0 (sv) 2001-07-05 2001-07-05 Astrazeneca Ab New compounds
WO2003013526A1 (en) 2001-08-08 2003-02-20 Merck & Co. Inc. Anticoagulant compounds
EP1444209A4 (en) 2001-11-07 2005-02-16 Merck & Co Inc INHIBITORS OF MITOTIC KINESIN
DE60222302T2 (de) 2001-12-06 2008-05-29 Merck & Co., Inc. Inhibitoren von mitotischem kinesin
US7244723B2 (en) 2001-12-06 2007-07-17 Merck & Co., Inc. Substituted furopyrimidinones as a mitotic kinesin inhibitors
ATE447577T1 (de) 2001-12-06 2009-11-15 Merck & Co Inc Mitotische kinesin-hemmer
EP1458726B1 (en) 2001-12-06 2009-07-15 Merck & Co., Inc. Mitotic kinesin inhibitors
WO2003049678A2 (en) 2001-12-06 2003-06-19 Merck & Co., Inc. Mitotic kinesin inhibitors
AR039209A1 (es) 2002-04-03 2005-02-09 Novartis Ag Derivados de indolilmaleimida
SE0203754D0 (sv) 2002-12-17 2002-12-17 Astrazeneca Ab New compounds
CA2536964A1 (en) 2003-04-25 2004-11-11 Ortho-Mcneil Pharmaceutical, Inc. C-fms kinase inhibitors
US20070149547A1 (en) 2004-02-12 2007-06-28 Celine Bonnefous Bipyridyl amides as modulators of metabotropic glutamate receptor-5
DE102004039789A1 (de) 2004-08-16 2006-03-02 Sanofi-Aventis Deutschland Gmbh Arylsubstituierte polycyclische Amine, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
CA2584507C (en) 2004-10-20 2016-04-26 Resverlogix Corp. Flavanoids and isoflavanoids for the prevention and treatment of cardiovascular diseases
WO2006048771A1 (en) 2004-11-04 2006-05-11 Addex Pharmaceuticals Sa Novel tetrazole derivatives as positive allosteric modulators of metabotropic glutamate receptors
DE602006019732D1 (de) 2005-07-11 2011-03-03 Novartis Ag Indolylmaleimidderivate
TW200815426A (en) 2006-06-28 2008-04-01 Astrazeneca Ab New pyridine analogues II 333
WO2008098208A2 (en) * 2007-02-08 2008-08-14 The Regents Of The University Of California Gnaq mutations in melanoma
WO2008106692A1 (en) * 2007-03-01 2008-09-04 Novartis Vaccines And Diagnostics, Inc. Pim kinase inhibitors and methods of their use
WO2009014637A2 (en) 2007-07-19 2009-01-29 Schering Corporation Heterocyclic amide compounds as protein kinase inhibitors
PE20091309A1 (es) 2007-12-21 2009-09-30 Astrazeneca Ab Derivados de ciclohexilo como inhibidores de acetil coenzima a carboxilasa
US8168794B2 (en) 2008-03-03 2012-05-01 Novartis Ag Pim kinase inhibitors and methods of their use
HUE047093T2 (hu) 2008-03-18 2020-04-28 Novartis Ag Bevonatoló eljárás szemészeti lencsékhez
JP5412519B2 (ja) * 2008-09-02 2014-02-12 ノバルティス アーゲー キナーゼ阻害剤としてのピコリンアミド誘導体
WO2010046780A2 (en) 2008-10-22 2010-04-29 Institut Pasteur Korea Anti viral compounds
US8703962B2 (en) 2008-10-24 2014-04-22 Purdue Pharma L.P. Monocyclic compounds and their use as TRPV1 ligands
HUE036068T2 (hu) 2008-12-19 2018-06-28 Vertex Pharma ATR kináz gátlószereiként alkalmazható pirazinszármazékok
CA2740195A1 (en) 2008-12-23 2010-07-01 Abbott Laboratories Anti-viral compounds
US20130023497A1 (en) 2009-06-08 2013-01-24 Chunlin Tao Triazine Derivatives and their Therapeutical Applications
US8415381B2 (en) 2009-07-30 2013-04-09 Novartis Ag Heteroaryl compounds and their uses
BR112012004836A2 (pt) * 2009-09-04 2019-09-24 Novartis Ag pirazinilpiridinas úteis para o tratamento de doenças proliferativas
WO2011068898A1 (en) 2009-12-01 2011-06-09 Rigel Pharmaceuticals, Inc. Protein kinase c inhibitors and uses thereof
US8748428B2 (en) * 2010-03-30 2014-06-10 Novartis Ag Use of a PKC inhibitor
US20130109682A1 (en) 2010-07-06 2013-05-02 Novartis Ag Cyclic ether compounds useful as kinase inhibitors
JP2014503528A (ja) 2010-12-14 2014-02-13 エレクトロプホレトイクス リミテッド カゼインキナーゼ１δ（ＣＫ１δ）阻害剤及びタウオパチーなどの神経変性疾患の治療におけるその使用
WO2012101064A1 (en) 2011-01-28 2012-08-02 Novartis Ag N-acyl pyrimidine biaryl compounds as protein kinase inhibitors
UY33930A (es) * 2011-03-04 2012-10-31 Novartis Ag Inhibidores novedosos de quinasas
JP2014506915A (ja) 2011-03-04 2014-03-20 ノバルティス アーゲー キナーゼ阻害剤としての四置換シクロヘキシル化合物
US9464065B2 (en) 2011-03-24 2016-10-11 The Scripps Research Institute Compounds and methods for inducing chondrogenesis
KR101410902B1 (ko) 2011-07-27 2014-06-20 아스트라제네카 아베 암 치료에 유용한 egfr 조절물질로서 2-(2,4,5-치환된-아닐리노)피리미딘 유도체
EP2861585B1 (en) * 2012-05-21 2019-01-09 Novartis AG Novel ring-substituted n-pyridinyl amides as kinase inhibitors
CN103570625A (zh) 2012-07-19 2014-02-12 南京英派药业有限公司 N-(3-杂芳基芳基)-4-芳基芳基甲酰胺和类似物作为Hedgehog通路抑制剂及其应用
US20150336960A1 (en) 2012-12-19 2015-11-26 Novartis Ag Aryl-substituted fused bicyclic pyridazine compounds
WO2014181287A1 (en) 2013-05-09 2014-11-13 Piramal Enterprises Limited Heterocyclyl compounds and uses thereof
JO3589B1 (ar) * 2014-08-06 2020-07-05 Novartis Ag مثبطات كيناز البروتين c وطرق استخداماتها
WO2019053595A1 (en) * 2017-09-12 2019-03-21 Novartis Ag INHIBITORS OF PROTEIN KINASE C FOR THE TREATMENT OF CHOROIDAL MELLANOMA

Also Published As

Publication number Publication date
US20190202809A1 (en) 2019-07-04
NI201700012A (es) 2017-03-08
IL250318A0 (en) 2017-03-30
CN106795151A (zh) 2017-05-31
SV2017005373A (es) 2018-05-03
AU2015298364B2 (en) 2018-08-16
CU24465B1 (es) 2020-01-03
TN2017000032A1 (en) 2018-07-04
US9452998B2 (en) 2016-09-27
US9845309B2 (en) 2017-12-19
ZA201700786B (en) 2021-05-26
RS59692B1 (sr) 2020-01-31
KR20230051605A (ko) 2023-04-18
PT3177608T (pt) 2019-12-03
US20210387962A1 (en) 2021-12-16
PH12017500215A1 (en) 2017-07-10
TWI680968B (zh) 2020-01-01
JO3589B1 (ar) 2020-07-05
HRP20192224T1 (hr) 2020-03-06
CL2017000290A1 (es) 2017-07-14
SI3177608T1 (sl) 2020-01-31
SG11201700664UA (en) 2017-02-27
EA201790323A1 (ru) 2017-06-30
US11059804B2 (en) 2021-07-13
EP3177608A1 (en) 2017-06-14
US20180179181A1 (en) 2018-06-28
CU20170010A7 (es) 2017-06-05
US10508101B2 (en) 2019-12-17
MY195488A (en) 2023-01-26
JP2017523215A (ja) 2017-08-17
MX2017001640A (es) 2017-09-01
UY36258A (es) 2016-04-01
AR101456A1 (es) 2016-12-21
ECSP17013903A (es) 2019-02-28
DOP2017000035A (es) 2017-04-30
IL250318B (en) 2020-05-31
AU2015298364A1 (en) 2017-02-16
TW201619148A (zh) 2016-06-01
PE20170241A1 (es) 2017-03-22
CN106795151B (zh) 2021-05-07
WO2016020864A1 (en) 2016-02-11
DK3177608T3 (da) 2019-12-09
BR112017002263A2 (pt) 2017-11-21
EP3177608B1 (en) 2019-09-18
KR20170033435A (ko) 2017-03-24
US11505541B2 (en) 2022-11-22
CA2956996C (en) 2023-01-03
CO2017001049A2 (es) 2017-05-31
HUE047862T2 (hu) 2020-05-28
CY1122407T1 (el) 2021-01-27
US20160347737A1 (en) 2016-12-01
US20200262814A1 (en) 2020-08-20
LT3177608T (lt) 2019-10-10
US20160046605A1 (en) 2016-02-18
GT201700025A (es) 2019-09-30
KR102518945B1 (ko) 2023-04-07
EA033361B1 (ru) 2019-10-31
JP6644765B2 (ja) 2020-02-12
CA2956996A1 (en) 2016-02-11
US20240308979A1 (en) 2024-09-19
AP2017009729A0 (en) 2017-02-28
NZ728604A (en) 2024-02-23
KR102605181B1 (ko) 2023-11-27
ES2754248T3 (es) 2020-04-16
CR20170036A (es) 2017-05-08
BR112017002263B1 (pt) 2022-11-29
CN113214246A (zh) 2021-08-06
EP3514151A1 (en) 2019-07-24

Similar Documents

Publication Publication Date Title
HK1259232A1 (zh) Menin-mll的取代抑制劑及其使用方法
IL286316A (en) New micro-dystrophins and related method of use
IL304117A (en) Anti-pvrig antibodies and methods of use
HK1252693A1 (zh) Egfr抑制劑及其使用方法
HK1258058A1 (zh) 抗tigit抗體和使用方法
HK1249513A1 (zh) Kras的稠合三環抑制劑及其使用方法
HK1252858A1 (zh) 抗cll-1抗體和使用方法
ZA201700786B (en) Protein kinase c inhibitors and methods of their use
IL250415B (en) Antibodies against pd-l and methods of using them
IL267291A (en) Actonucleotidase inhibitors and methods of using them
IL259801A (en) ezh2 inhibitors and methods of using them
IL251477A0 (en) Anti-ang2 antibodies and methods of use
EP3265093A4 (en) Tricyclic kinase inhibitors of melk and methods of use
HK1257171A1 (zh) 間變性淋巴瘤激酶（alk）和絲氨酸富集蛋白激酶 （sppk）的抑制劑及其使用方法
HK1258850A1 (zh) 抗tpbg抗體及使用方法
SG11201605915WA (en) Furo-3-carboxamide derivatives and methods of use
ZA201606450B (en) Compounds and their methods of use
IL266344A (en) Inhibitors of mtor-deptor interactions and methods of use thereof